Related Experiment Video
Updated: Apr 7, 2026
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
3.0K
[Progress in Antiretroviral Therapy and HAND]
Yusuke Matsui1, Akifumi Takaori-Kondo
1Department of Hematology and Oncology, Graduate School of Medicine.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|July 11, 2015
Summary
Over 20,000 individuals in Japan live with human immunodeficiency virus (HIV). While antiretroviral therapy (ART) improves outcomes, long-term use can lead to HIV-associated neurocognitive disorders (HAND).
Area of Science:
- Virology
- Neurology
- Pharmacology
Context:
- Over 20,000 people in Japan are living with HIV.
- Antiretroviral therapy (ART) has transformed HIV prognosis.
- Long-term ART presents new clinical challenges.
Purpose:
- To review advancements in anti-HIV therapies.
- To explain HIV-associated neurocognitive disorders (HAND).
- To highlight HAND as a complication of HIV infection.
Summary:
- This article details the evolution of anti-HIV treatment strategies.
- It defines and discusses HIV-associated neurocognitive disorders (HAND).
- The focus is on understanding HAND in the context of modern HIV management.
Impact:
- Provides an overview of current and historical anti-HIV treatments.
- Increases awareness of HAND as a significant complication.
- Informs clinicians and researchers about the long-term implications of HIV therapy.
Related Concept Videos
01:10Retrovirus Life Cycles
50.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:29Drugs Affecting Neurotransmitter Synthesis
2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
873
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
873